NCT01659034View on ClinicalTrials.gov

Short and Optimal Duration of Dual Antiplatelet Therapy Study

PHASE4CompletedINTERVENTIONAL
Enrollment

1,525

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
Coronary Artery Disease
Interventions
DRUG

Thienopyridine for 3 months

Trial Locations (1)

606-8507

Department of Cardiovascular Medicine, Kyoto University Hospital, Kyoto

All Listed Sponsors
lead

Takeshi Morimoto

OTHER

NCT01659034 - Short and Optimal Duration of Dual Antiplatelet Therapy Study | Biotech Hunter | Biotech Hunter